Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 24123087)

1.

Dopamine overdose hypothesis: evidence and clinical implications.

Vaillancourt DE, Schonfeld D, Kwak Y, Bohnen NI, Seidler R.

Mov Disord. 2013 Dec;28(14):1920-9. doi: 10.1002/mds.25687. Epub 2013 Oct 9. Review.

2.

Effect of dopaminergic medications on the time course of explicit motor sequence learning in Parkinson's disease.

Kwak Y, Müller ML, Bohnen NI, Dayalu P, Seidler RD.

J Neurophysiol. 2010 Feb;103(2):942-9. doi: 10.1152/jn.00197.2009. Epub 2009 Dec 16.

3.

Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.

Fera F, Nicoletti G, Cerasa A, Romeo N, Gallo O, Gioia MC, Arabia G, Pugliese P, Zappia M, Quattrone A.

Brain Res Bull. 2007 Sep 14;74(1-3):75-83. Epub 2007 Jun 6.

PMID:
17683792
4.

The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI.

MacDonald PA, MacDonald AA, Seergobin KN, Tamjeedi R, Ganjavi H, Provost JS, Monchi O.

Brain. 2011 May;134(Pt 5):1447-63. doi: 10.1093/brain/awr075.

6.
7.

Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.

MacDonald AA, Monchi O, Seergobin KN, Ganjavi H, Tamjeedi R, MacDonald PA.

Mov Disord. 2013 Feb;28(2):153-60. doi: 10.1002/mds.25152. Epub 2012 Nov 19.

PMID:
23165957
8.

Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients.

Kulisevsky J, García-Sánchez C, Berthier ML, Barbanoj M, Pascual-Sedano B, Gironell A, Estévez-González A.

Mov Disord. 2000 Jul;15(4):613-26.

PMID:
10928571
9.

Brain dopaminergic modulation associated with executive function in Parkinson's disease.

Farid K, Sibon I, Guehl D, Cuny E, Burbaud P, Allard M.

Mov Disord. 2009 Oct 15;24(13):1962-9. doi: 10.1002/mds.22709.

PMID:
19672989
10.

Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition.

Rowe JB, Hughes L, Ghosh BC, Eckstein D, Williams-Gray CH, Fallon S, Barker RA, Owen AM.

Brain. 2008 Aug;131(Pt 8):2094-105. doi: 10.1093/brain/awn112. Epub 2008 Jun 24.

11.

Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders.

Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, Juncos JL, Obeso JA, Bezard E.

Lancet Neurol. 2009 Dec;8(12):1140-9. doi: 10.1016/S1474-4422(09)70287-X. Review.

PMID:
19909912
12.

Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.

Thobois S, Ardouin C, Lhommée E, Klinger H, Lagrange C, Xie J, Fraix V, Coelho Braga MC, Hassani R, Kistner A, Juphard A, Seigneuret E, Chabardes S, Mertens P, Polo G, Reilhac A, Costes N, LeBars D, Savasta M, Tremblay L, Quesada JL, Bosson JL, Benabid AL, Broussolle E, Pollak P, Krack P.

Brain. 2010 Apr;133(Pt 4):1111-27. doi: 10.1093/brain/awq032. Epub 2010 Mar 17.

13.

Dopaminergic therapy removal differentially effects learning in schizophrenia and Parkinson's disease.

Weickert TW, Mattay VS, Das S, Bigelow LB, Apud JA, Egan MF, Weinberger DR, Goldberg TE.

Schizophr Res. 2013 Sep;149(1-3):162-6. doi: 10.1016/j.schres.2013.06.028. Epub 2013 Jul 3.

14.

Dopaminergic effects on cognitive performance in patients with Parkinson's disease.

Lange KW, Paul GM, Naumann M, Gsell W.

J Neural Transm Suppl. 1995;46:423-32.

PMID:
8821078
15.
16.

[Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].

Klivényi P, Vécsei L.

Ideggyogy Sz. 2007 Jan 20;60(1-2):61-4. Review. Hungarian.

PMID:
17432097
17.

The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.

Stocchi F.

Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S9-S15. doi: 10.1016/S1353-8020(09)70005-7. Review.

PMID:
19131046
18.

Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management.

O'Sullivan SS, Evans AH, Lees AJ.

CNS Drugs. 2009;23(2):157-70. doi: 10.2165/00023210-200923020-00005. Review.

PMID:
19173374
19.

Medication impairs probabilistic classification learning in Parkinson's disease.

Jahanshahi M, Wilkinson L, Gahir H, Dharmaindra A, Lagnado DA.

Neuropsychologia. 2010 Mar;48(4):1096-103. doi: 10.1016/j.neuropsychologia.2009.12.010. Epub 2009 Dec 16. Erratum in: Neuropsychologia. 2011 Oct;49(12):3517. Dharminda, Angeline [corrected to Dharmarinda, Angeline]. Neuropsychologia. 2012 Jul;50(8):2129. Dharmarinda, Angeline [corrected to Dharmaindra, Angeline].

PMID:
20006629
20.

Functional brain imaging of cognitive dysfunction in Parkinson's disease.

Hirano S, Shinotoh H, Eidelberg D.

J Neurol Neurosurg Psychiatry. 2012 Oct;83(10):963-9. doi: 10.1136/jnnp-2011-301818. Epub 2012 Jul 17. Review.

PMID:
22807560
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk